Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Apr 19, 2021
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the agenda...
-
Apr 16, 2021- Darovasertib monotherapy results in 57% 1-year Overall Survival (OS) Rate in predominantly 2L / 3L and heavily pre-treated (out to 7L / 8L) MUM patients, where historical 1-year OS Rate has been reported at 37%
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced clinical...
-
Apr 15, 2021
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that the...
-
Apr 15, 2021- IDE397 demonstrates significant single-agent anti-tumor activity in a 40-plus MTAP-deletion PDX study, including tumor regressions, across major solid tumor types, such as NSCLC, gastric, esophageal, and bladder cancers (AACR 2021)
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced...
-
Mar 23, 2021- Initiated Phase 1 clinical trial for IDE397, a potential best-in-class MAT2A inhibitor for patients having tumors with MTAP-deletion
IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business...